Novartis (VTX:NOVN) Given a CHF 89 Price Target by Deutsche Bank Analysts
Deutsche Bank set a CHF 89 price target on Novartis (VTX:NOVN) in a report released on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.
A number of other research firms have also recently commented on NOVN. Morgan Stanley boosted their price target on shares of Intact Financial from C$125.00 to C$128.00 in a research note on Thursday, May 30th. UBS Group set a €83.00 ($96.51) price target on shares of Schneider Electric and gave the stock a buy rating in a research note on Thursday, June 27th. Kepler Capital Markets set a €160.00 ($186.05) price target on shares of Pfeiffer Vacuum Technology and gave the stock a buy rating in a research note on Tuesday, May 21st. Barclays reissued a buy rating and issued a $417.00 price target on shares of Boeing in a research note on Monday, April 8th. Finally, Credit Suisse Group cut their price target on shares of FOX from $51.00 to $45.00 and set an outperform rating for the company in a research note on Monday, June 3rd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. Novartis has an average rating of Hold and an average target price of CHF 89.41.
Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Further Reading: What is the price-sales ratio?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.